🔗 Share this article

While America continues making sweeping revisions to its immunization schedules, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on coronavirus shots in the global health crisis and has concentrated on alleged deaths after Covid vaccination in her short position at the Food and Drug Administration.

Planned Shifts to Childhood Immunization Schedule

Health officials planned to reveal sweeping revisions to the childhood immunization program in December, bringing the US with the Danish national calendar, sources say – a significant shift that would place the US out of alignment with a large portion of the world with no evidence for improved outcomes. This reveal has been delayed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to run the division this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending some childhood vaccine recommendations in the US in order to be more similar to the Danish model, a society with universal health coverage and a population about the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccines – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Background

Høeg has little discernible experience in pharmaceutical research, regulation or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in industry regulation.”

Former directors of CBER would “be deeply familiar with legal statutes and the science of medication creation”, said Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who ran the center have had.”

The drug center has an enormous workload at the agency, the former commissioner stated.

“Everybody just pays attention on the novel medication approvals, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and more, and all of those need to be managed,” Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a major administrative component to the position, which oversees more than 5,000 staff members. “It is a huge leadership role, if you do it right,” she added.

Agency Reaction and Disputed Programs

In response to questions about Dr. Høeg's qualifications and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a press secretary responded that the “concerns stem from flawed assumptions”.

“Her experience is consistent with the responsibilities of her position,” the representative stated, noting the months Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a disputed expedited therapy clearance system that reportedly concerned her predecessors. “By what process are these therapies being chosen for this fast-track system? Who takes the choices?” Howard questioned. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he said, “the agency seems to be moving towards more relaxed regulations of all drugs, except for shots.”

Documented Track Record on Immunizations

With vaccines, Høeg has a clearer, if troubling, history, Howard observe. She released a research paper using non-validated volunteer-provided data to estimate the incidence of heart inflammation after Covid immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the current government included altering rules for novel immunizations and halting “non-essential” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of excluding teenage boys from receiving Covid vaccines.

“She’s an thorough ideologue who starts off with her preconceived notions and reverse-engineers to accommodate the evidence in a very misleading, untruthful fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined other skeptics, {like|